cendakimab (CC-93538) - AbbVie, BMS
lirentelimab (AK002) - Allakos
Cinqair (reslizumab) - Merck (MSD), UCB, Teva
Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen
Nucala (mepolizumab) - GSK
Fasenra (benralizumab) - AstraZeneca
Dupixent (dupilumab) - Sanofi, Regeneron
dectrekumab (QAX576) - Novartis
http://www.ncbi.nlm.nih.gov/pubmed/38338983
 
Alessandro Barone; Erminia Ridolo; Francesca Nicoletta; Marcello Montagni; Martina Ottoni; Silvia Peveri
 
Feb 10, 2024
 
Prev Next